Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P15907
UPID:
SIAT1_HUMAN
Alternative names:
B-cell antigen CD75; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1; ST6Gal I; Sialyltransferase 1
Alternative UPACC:
P15907; A8KA14; B2R513; D3DNV3
Background:
Beta-galactoside alpha-2,6-sialyltransferase 1, known by alternative names such as B-cell antigen CD75, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1, ST6Gal I, and Sialyltransferase 1, plays a crucial role in cellular communication. It transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates, a process vital for the proper functioning of glycoproteins and glycolipids.
Therapeutic significance:
Understanding the role of Beta-galactoside alpha-2,6-sialyltransferase 1 could open doors to potential therapeutic strategies. Its pivotal function in the modification of glycoproteins and glycolipids suggests its involvement in a wide range of cellular processes, making it a target of interest in drug discovery.